↓ Skip to main content

ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms

Overview of attention for article published in Clinical Proteomics, January 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#1 of 178)
  • High Attention Score compared to outputs of the same age (98th percentile)

Mentioned by

news
17 news outlets
blogs
1 blog
twitter
7 tweeters
patent
1 patent
facebook
2 Facebook pages

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
17 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
Published in
Clinical Proteomics, January 2016
DOI 10.1186/s12014-016-9103-3
Pubmed ID
Authors

D. James Morré, Brandon Hostetler, David J. Taggart, Dorothy M. Morré, A. W. Musk, Bruce W. S. Robinson, Jenette Creaney

Abstract

Malignant mesothelioma is an aggressive, almost uniformly fatal tumor, caused primarily by exposure to asbestos. In this study, serum presence of mesothelioma-specific protein transcript variants of ecto-nicotinamide adenine dinucleotide oxidase disulfide-thiol exchanger 2 (ENOX2), a recently identified marker of malignancy, were investigated using the ONCOblot tissue of origin cancer detection test. Sequential serum samples collected from asbestos-exposed individuals prior to the development of frank mesothelioma were assayed for ENOX2 presence by 2-D gel immunoblot analysis to determine how long in advance of clinical symptoms mesothelioma-specific ENOX2 transcript variants could be detected. Two mesothelioma-specific ENOX2 protein transcript variants were detected in the serum of asbestos-exposed individuals 4-10 years prior to clinical diagnosis of malignant mesothelioma (average 6.2 years). Either one or both ENOX2 protein transcript variants indicative of malignant mesothelioma were absent in 14 of 15 subjects diagnosed with benign pleural plaques either with or without accompanying asbestosis. In a population of asbestos-exposed subjects who eventually developed malignant mesothelioma, ENOX2 protein transcript variants characteristic of malignant mesothelioma were present in serum 4-10 years in advance of clinical symptoms. As with all biomarker studies, these observations require validation in a larger, independent cohort of patients and should include prospective as well as retrospective sampling.

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Canada 1 6%
Unknown 16 94%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 24%
Student > Ph. D. Student 4 24%
Student > Doctoral Student 2 12%
Student > Bachelor 1 6%
Lecturer 1 6%
Other 3 18%
Unknown 2 12%
Readers by discipline Count As %
Medicine and Dentistry 4 24%
Biochemistry, Genetics and Molecular Biology 3 18%
Agricultural and Biological Sciences 2 12%
Immunology and Microbiology 1 6%
Social Sciences 1 6%
Other 3 18%
Unknown 3 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 146. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 December 2017.
All research outputs
#99,533
of 13,521,399 outputs
Outputs from Clinical Proteomics
#1
of 178 outputs
Outputs of similar age
#3,580
of 336,174 outputs
Outputs of similar age from Clinical Proteomics
#1
of 1 outputs
Altmetric has tracked 13,521,399 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 178 research outputs from this source. They receive a mean Attention Score of 3.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 336,174 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them